Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer.

ABSTRACT:

Background/aims

Programmed death-ligand 1 (PD-L1) expression, a validated predictive biomarker for anti-PD-1/PD-L1 inhibitors, is reported to change over time. This poses challenges during clinical application in non-small cell lung cancer.

Methods

This study included patients with non-small cell lung cancer who underwent surgery or biopsy and evaluation of PD-L1 expression in tumor cells via immunohistochemistry more than twice. We set the threshold of PD-L1 positivity to 10% and categorized patients into four groups according to changes in PD-L1 expression. Clinicopathologic information was collected from medical records. Statistical analyses, including Fisher's exact test and log-rank test, were performed.

Results

Of 109 patients, 38 (34.9%) and 45 (41.3%) had PD-L

SUBMITTER: Nam CH 

PROVIDER: S-EPMC8273838 | biostudies-literature | 2021 Jul

REPOSITORIES: biostudies-literature